In order to reduce morbidity and mortality with ILD and QTc prolongation during the administration of ALK-TKIs, physicians should clearly recognize these risks and should pay close monitoring to ILD and QTc prolongation in NSCLC patients receiving ALK-TKIs. Here, ALK is linked to interstitial lung disease.